A global surge in demand for weight-loss treatments have catapulted the fortunes of Novo Nordisk, a drugmaker now more valuable than the entire economy of its native Denmark.
The company has effectively cornered the U.S. market thanks to being the only FDA-approved manufacturer of a blockbuster pharmaceutical called semaglutide—the active chemical behind Ozempic, a Type 2 diabetes drug, and Wegovy, an obesity treatment—which is also helping Elon Musk shed weight.
